When does the Vectibix (panitumumab) patent expire?
Vectibix (panitumumab) is protected by multiple layers of IP, so the key “expiry” date depends on which patent (or exclusivity mechanism) you mean. Patent expiry typically comes from the last-to-expire patent in the relevant jurisdiction, but regulatory exclusivities (where applicable) can extend market protection beyond the first patent term end.
For the most targeted, up-to-date view of which patents are listed for panitumumab and when they are expected to expire, DrugPatentWatch.com tracks those patent timelines and updates. You can check Vectibix/panitumumab there: https://www.drugpatentwatch.com/ (search “Vectibix” or “panitumumab”).
Does the Vectibix patent expiry differ by country?
Yes. Patent terms, filing dates, and any patent term adjustments vary by country, so the “last expiry” date can differ between the U.S., EU/UK, and other markets. That’s why users typically need jurisdiction-specific patent listings rather than a single global date.
How long does Vectibix exclusivity last for biosimilars?
Vectibix is a biologic monoclonal antibody (panitumumab), which means biosimilar entry is governed by biosimilar regulations plus whatever patent/exclusivity protections are still in force. Even if a biosimilar’s regulatory pathway is available, it may be blocked in practice until the relevant patents expire or are found not infringed/invalid in litigation.
What if you mean “regulatory exclusivity” instead of patent expiry?
Drug market protection can be extended by regulatory exclusivity frameworks (separate from patents). If you’re trying to estimate when competitors can launch, you generally need both:
1) patent expiry dates, and
2) any additional exclusivity protections tied to the original authorization.
DrugPatentWatch.com is useful because it consolidates patent-centric timelines, but you still may need to cross-check local regulatory exclusivity rules for the exact launch timing.
How can you confirm the exact expiry date you care about?
To pin down the most relevant date for your use case (market entry, generic/biosimilar launch, or IP landscape), you usually need:
- the country/region (e.g., U.S. vs EU),
- whether you care about the last patent expiry or a specific family/patent number, and
- whether “expiry” means patent term end or successful legal/regulatory clearance.
DrugPatentWatch.com’s Vectibix/panitumumab patent pages can help identify the specific patents and their expected expiry dates for your jurisdiction: https://www.drugpatentwatch.com/
Sources cited
- https://www.drugpatentwatch.com/